bannerbanner

The Role of Orexins In Sleep-Wake Regulation

The orexin signaling system is a central promoter of wakefulness

NORMAL SLEEP-WAKE REGULATION

Daytime

Daytime

In the daytime,
orexins help us
stay awake

Night

Night

At night,
orexin activity is very low
letting us sleep

INSOMNIA

Insomnia

Insomnia

In insomnia,
excess orexins prevent
us from sleeping

DAYVIGO

DAYVIGO

DAYVIGO
DAYVIGO blocks
orexin activity

Normal sleep-wake regulation occurs when the wake-promoting pathway predominates during the day, and the sleep-promoting pathway predominates at night.

In insomnia, patients have difficulty falling asleep or staying asleep as a result of an imbalance and conflict between these two pathways.

Blocking the binding of wake-promoting orexins is thought to suppress the wake drive.

brain
  • Orexin-producing neurons
  • Wake-controlling neurons expressing orexin receptors

What is DAYVIGO™

  • A dual orexin receptor antagonist (DORA). The Orexin neuropeptide
    signaling system is a central promoter of wakefulness.
  • Blocking the binding of wake-promoting neuropeptides orexin A and
    orexin B to receptors OX1R and OX2R is thought to suppress wake drive

DAYVIGO is an antagonist of both orexin receptors. It does not
work by increasing GABA activity2

GABA = gamma aminobutyric acid
  • Orexin-producing neurons
  • Wake-controlling neurons expressing orexin receptors
Mode of Action
See How DAYVIGO Works
play
asleep nuerons
awake neurons

Sleep disturbance may be the presenting manifestation of a physical and/or psychiatric disorder.
Consequently, a decision to initiate symptomatic treatment of insomnia should only be made after the
patient has been carefully evaluated.

DAYVIGO™ is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or
sleep maintenance.

Click here for additional safety information and for a link to the product monograph, discussing
contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical
use.

2. Beuckmann CT, Suzuki M, Ueno T, et al. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist. J Pharmacol Exp Ther. 2017;362(2):287 -95